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ABBREVIATIONS
ACTH _ ADRENOCORTICOTROPIC HORMONE
ADH - ANTIDIURETIC HORMONE
PTH - PARATHYROID HORMONE
HGH _ HUMAN GROWTH HORMONE
. HCG - HUMAN CHORIONIC GONADOTROPHS
5HT _ 5-HYDRQXYTRYPTAMINE
INTRODUCTION
The recognition that certain clinical syndromes of
endocrine hyperfunction can be due to ectopic polypeptide hormone
production by tumours has been among the major developments in
endocrinology in the last decade. A hormone is defined as ectopic
when it is secreted by a tumour derived from a tissue not normally
engaged in the production of that hormone. (41) e.g. an oat cell
carcinoma of lung secreting ACTS (93) or an islet cell carcinoma
of pancreas secreting ADH (40).
It is interesting that neoplastic cells can acquire the
capacity to produce specialized polypeptides such as hormones and
this phenomenon would appear to reflect significant alterations of
genetic regulation (5,4). Ectopic hormone production by tumours
is a pathological event which raises many important questions
concerning cell differentiation and its control.
EVIDENCE FOR HORMONE PRODUCTION BY TUMOURS
Despite numerous reports of ectopic hormone producing
tumours, few have given conclusive evidence for ectopic production.
Indeed, one recent critical evaluation (8) of reports of tumours
associated with Cushing's syndrome i.e. ectopic ACTH secretion,
rejected approximately 25% of these because of inadequate evidence
of ACTH secretion by the tumours or misidentification of the tumour' s
histological type. To avoid such inaccuracy, several'authors have
suggested criteria for the ectopic production of a hormone by a
tumour (68,77,78). These criteria are based on the existing evidence
for. ectopic hormone production, and are as follows:-
1. Association of a tumour with an endocrine excess syndrome
It was from such associations (72,73) that the concept
of ectopic hormones emerged, but now this is nothing more than a
starting point for diagnosis. High plasma levels in a tumour-bearing
patient need not be result of ectopic production as there could be
a coexisting pathological condition e.g. idiopathic Cushing's syndrome.
2, Demonstration of the presence of hormone in the tumour tissue
Tumour cells, suspected of being hormone-producing, have
been shown to have concentrations of hormone in their cytoplasm and
this can be demonstrated in two ways:-
i) Biochemical extraction of the hormone from the tumour.
The extract is then tested by bioassay (57)•
ii) Immunofluorescent techniques. This involves using
fluorescent-labelled antisera for the suspected hormone (29»41)• and
requires isolated and purefied natural hormones for production of the
antisera.
Positive results, using either of these methods, do not
necessarily prove that the tumour has synthesized that hormone (40).
Some tumours seem capable of selectively extracting hormones from the
circulation (35) and- this phenomenon has also been reported for
tuberculous lesions which had high concentrations of ADH present (74)•
3. Demonstration of an arterio-venous concentration gradient for
the hormone across the tumour bed
Arterio-venous gradients have been reported for a variety
of hormones, namely ACTH (10,71), PTH (14,17,39), gbnadotrophins (6,23),
and HGH (78), and these findings offer more convincing evidence
for hormone secretion by tumours. Difficulties can arise, however,
when tumours have a dual blood supply e.g. in the lung (40).
4. Lack of suppression of secretion due to autonomous production.
Despite isolated pieces of evidence for periodic hormonogenesis
in tumours (9) and for stimulation of production by normal releasing
factors (11,36), most ectopic hormone producing tumours appear to
secrete hormone continuously and are not subject to the feedback
control of normal endocrines (10,29,35,41,71)• Autonomous production
of hormone by the tumour can be demonstrated by the use of substances
fehiah which interfere with the normal endocrine systems e.g. metyrapone
inhibits the 11-hydroxylation stage in the synthesis of Cortisol and,
in the normal subject, leads to increased plasma ACTH levels. In
cases where an ectopic ACTH secreting tumour is present, the plasma
ACTH remains unaltered after metyrapone (35)• Similarly, hydrocortisone
or dexamethasone administration fails to suppress ACTH levels (10,29,71)•.
The most striking finding in this context is the marked
atrophy of the endocrine gland normally associated with a hormone
which was present in very high levels before death (69).
5. In vitro synthesis and release of hormone
Perhaps the most convincing evidence for ectopic hormone
production comes from cell culture work in which tumour cells have
been shown to synthesize hormones. Cells cultured in vitro from
an anaplastic (probably oat-cell) lung carcinoma have been shown
to incorporate radioactively labelled leucine into an HGH-like
substance (32) (the radioactivity appeared in a fraction which separated
out alongside standard HGH in paper chromatography and gel filtration),
HGH was also detected by radioimmunoassay in the supernatant and was
found to accumulate over a period of time. Similar results have
been obtained for bronchogenic carcinomas synthesizing ADH (28),
ACTH (36) and HCG (6). The latter study, however, merely demonstrated
an increase in radioimmunoassayable hormone in the supernatant. This
does not necessarily indicate de novo synthesis as hormone could be
stored in the cells and be released on cell death.
From the above discussion it can be readily appreciated that
it is difficult to produce direct evidence of hormone synthesis by a
tumour, althouhg the accumulation of evidence from many sources
does render ectopic hormone synthesis by tumours an entity. Since,
however, some explanations of the ectopic hormone phenomenon rely
on knowing the exact cells of origin (8) , it is imperative that
accurate evidence be obtained. This is particularly difficult
when a tumour contains several cell types.
c. NATURE OF THE HORMONES SECRETED BY TUMOURS
Crucial to the consideration of the mechanism of ectopic
hormone production is the question of whether the hormones secreted
are identical to the normal ones. As yet, no amino-acid sequence
has been obtained for an ectopic hormone but information regarding their
structure has come from biochemical, radioimmunoassay and chromatographic
techniques. (41,42) These preliminary characterizations suggest that
the hormones are indeed similar to the native ones although there
is some contradictory evidence. Ectopic ACTH has been studied
/r
intensively (29,36,41,51>52,53»97) it appears that tumours
tend to secrete a 'big' form of ACTH (29,36,41»97) because the
material extracted with ACTH-like activity has the chromatographic
mobility of a larger molecule ( estimated m. w. of 7000 daltons c. f.
m.w. of normal pituitary ACTH of 4500 daltons). A credible
explanation for this (31) is that it represents a precursor form
of ACTH and that tumours may lack the enzyme(s) necessary to
convert it to the normal circulating form. This hypothesis is
supported by the finding of 'big' ACTH in the normal pituitary (97).
It is interesting to note that two studies (29,35) have found
that, in biopsy or autopsy samples of lung carcinomas from patients
with no evidence of ectopic ACTH syndrome, there was a
significant concentration of 'big* ACTH in the tumour c.f. adjacent
lung tissue. 'Big' ACTH has a very low biological potency (4i%
normal ACTH) and it is possible that ectopic synthesis of ACTH is more
common than imagined but goes unnoticed. Moreover, it is conceivable
tha t the only cases tested are ones in which the hormone produced
is similar enough to the normal one to produce a clinical syndrome
while other tumours may be synthesizing polypeptides which partially
resemble the native hormone but whose hormonal potency is low i.e.
diagnostic procedures may be biasing results.
DISCUSSION OF THEORIES ON MECHANISM OF ECTOPIC HORMONE
SYNTHESIS BY TUMOURS
Since ectopic hormone production by tumours was recognized
as an entity, several theories have been advanced to explain the
mechanism involved. These are as follows
i) Sponge hypothesis
Unger (81) thought it highly unlikely that disorganized cells
such as neoplastic cells could suddenly acquire the specialized
synthetic functions of endocrine cells. Instead, he introduced the
'sponge' hypothesis which stated that large quantities of hormone accumulated
in the tumour mass as a resultof increased hormone uptake and/or
decreased degradation by neoplastic cells.. If, then, the patient
survived long enough to develop large hormone-laden tumour masses,
accelerated brea kdown of malignant cells in rapidly enlarging
tumours could result in an -unregulated release of large quantities
of hormone and the appearance of hormone excess. Support for
this theory comes from the finding (30) that neoplastic cells are
capable of taking up fluorescently-labelled proteins directly.
This process is distinct from hhe known capacity of tumour cells,
and all rapidly growing tissues, to sequestrate amino-acids from
the common metabolic pool. In addition to this, the previously
mentioned reports of concentration of hormone (ADH) in tuberculous
lesions (74»83) could be as a result of this 'sponge' effect.
Unger's hypothesis, however, is -unacceptable for the
following reasons
a) the concentrations of hormone in the tumour cell cytoplasm
(see B.2) were approximately 4000-6000 X the plasma levels. It is
difficult to envisage such a concentration occurring by a 'sponge'
process.
b) certain types of tumours are associated with particular hormones (8).
This non-random association is not likely to.occur if the mechanism
merely involves 'trapping' of the hormone in tumour cells.
c) the evidence for hormone synthesis by cell cultures from
tumours (6,28,32) and, in particular, the demonstration of HCG
production in males (28) renders the 'sponge' hypothesis unlikely.
ii) Random genetic de repression
Prom experiments such as those in which nuclei have been
transplanted from differentiated adultcells to enucleated ova (in frogs)
and normal development has ensued (3»27>33)» it is known that all cells
possess and retain the genetic information for the synthesis of all
proteins. Differentiation is thought to involve progressive repression
of genes and, indeed, it has been shown that there is a reduction in
DNA template activity in the course of cell differentiation (47) ( the
technique involved the use of a histochemical method for highlighting
active DNA template along with high resolution electron microscopy)
The random derepression hypothesis (26) postulates that the
genetic derepression caused by neoplasia (4»75) can lead to the production
of any polypeptide or protein depending on which part of the genome
is derepressed. Ectopic hormone synthesis is merely one example
of this effect.
As yet, examples of ectopic polypeptide hormones only
have been obtained. Since steroid hormone production requires
the presence of several enzymes, it is unlikely that these would
all appear as a result of random derepression (12,30). This
would seem to support the hypothesis but random derepression, However,
fails to explain why certain tumours e.g. carcinomas of breast, colon
and prostate, are very rarely associated with ectopic hormones (49)
whereas other tumours are frequently involved (8) e.g. islet-cell
carcinomas, medullary carcinoma of thyroid, oat-cell carcinoma of
lung and carcinoid tumours.
iii) Selective genetic derepression
As mentioned in the previous section, neoplasia involves
dedifferentiation of cells with the acquisition of an earlier
competence (4*41*48,77*92). This effect is highlighted by the
large number of reports concerning the production of fetal-specific
substances by tumours e.g.c*-fetoprotein, carcinoembryonic antigen etc.
Evidence is obtained mainly by immunological cross-reaction studies
i.e. antibodies raised to tumour antigens will also react with fetal
cell products (1,2,3,4,19*22,37*75,76,79)• The achievement (in mice)
of a degree of immunization against oncogenesis using irradiated
fetal cells as immunogens (1,18,22,97) further indicates a relationship
between fetal and tumour cells.
If neoplasia does cause cells to acquire an earlier
competence, then the non-random pattern of ectopic hormone production
may be determined by the embryological origin of the cells concerned (8,40,55)
This factor, in addition to the morphology and histochemistry of the
tumours involved, has been studied intensively (12,24,40,48,50,55,
56,60,66,63,93,94) and the most important development has been the
formulation of the AFUD concept by Pearse (55,56,57,58,60).
The APUD cell series comprises cells found chiefly in
the foregut and its derivatives i.e. pancreas, bronchi, C-cells of
thyroid etc., and Pearse grouped them together initially because of
the cytochemical and ultrastructural characteristics they had in common
( see Table 1). Of particular significance is the capacity of these
cells to take up amine precursors (L-DOPA, 5-Hydroxytryptophan)
and. decarboxylate them to produce amines. This characteristic, which
resembles the process in nerve terminals, gave these cells their
mnemonic name ( Amine Precursor Uptake and Decarboxylation).
Apart from the properties listed in Table 1., a large number of
the proposed APUD series are polypeptide-secreting endocrine glands
(see Table 2.(
Pearse postulates that APUD cells are neuroectodermal
in origin (55»56,57) and, indeed, evidence obtained using the
APUD-FIF (APUD formaldehyde induced fluorescence) method (56)
to trace the migration of APUD cells from the neural crest (cells
with APUD characteristics can be seen here at 72hrs in the chick
embryo) supports Pearse's hypothesis. (50,56,57*58) It bas been
suggested (86) that the APUD cell is, therefore, a pluripotential
stem cell, in respect of both amine-handling and polypeptide
hormone synthesis, which migrates from the neural crest to endoderm
and its derivatives to form the polypeptide-secreting endocrine glands.
Despite some evidence,from partial neural crest ablation studies ,
which indicates that neural crest cells are developmentally labile (96),
ther is no positive proof of the APUD cells being pluripotential.
What does seem to support this idea is the way in which the APUD
concept provides an explanation for the pattern of ectopic hormone
secretion. Many of the tumours associated with ectopic hormone
production are derived from AFUD cells (40,86 and Table 5») and this
could be explained by their common embryological origin. If, as
suggested, APUD cells are pluripotent stem cellsw which differentiate
into one or other of the peptide endocrine glands, then dedifferentiation
in neoplasia would allow any member of the APUD series to synthesize
and secrete a variable selection of the whole series of polypeptide
hormones (86,91) e.g. ACTH from medullary carcinoma of thyroid or
from an islet-cell carcinoma. It could also account for the secretion
of 5-HT frequently, associated with these tumours (48),
Levine and Metz (40), in their classification of ectopic
hormone producing tumours, have made G2oup 1 all those tumours derived
from APUD cells (see Table 3) and- the term APUDOMA has emerged (15, 60,61,91).
An APUDOMA can be defined as a tumour derived from an APUD cell and
thus neuroectodermal in quality, which is secreting either its normal hormone
or one or more of the hormones of the APUD series, (61)
Since the APUD concept was suggested as a possible
explanation for the pattern of ectopic hormone production, there
has been a sjready accumulation of evidence in support of it e.g. the
oat-cell, which is reknowned for its association with ectopic
hormones, is ultrastructurally very similar to the bronchial
carcinoid cell which is derived from the Feyrter or Kultschitsky
cell (an APUD cell). The oat-cell is probably an anaplastic
derivative of a Feyrter cell (12,34*94)• The evidence so far,
however, does not account for the occasional reports of production of
PTH by tumours possessing APUD characteristics because the parathyroid
is presently regarded as being of endodermal origin. Ther are
also reports of production of APUD hormones by tumours of known
endodermal or mesodermal origin (40,68). These findings may
reflect bad documentation or, possibly, an even greater degree of
derepression than usual i.e. the association of certain tumours with
a hormone is statistical rather than absolute. An alternative explanation
(85) is that cell hybridization, which has been shown to occur
in malignant tumours (7,38,43>87,88,), may play a part in the
genesis of ectopic humoral syndromes. In those cases in which
APUD hormones are secreted by tumours of non-APUD origin, the tumour
cells might have fused with neuroectodermal cells. This idea semms
rather unlikely and has no supporting evidence.
The APUD concept, therefore, appears to account reasonably
well for the association of certain tumours with certain hormones.
The implication of this, from a genetic point of view, is that, while
all cells are genetically totipotent, the genes coding for polypeptide
hormone synthesis are more easily derepressed in APUD cells. The
molecular mechanism of cell differentiation is incompletely
understood (16,20,33,47>75»84) but this seems to suggests that
the degree of repression, and, hence, the ease of derepression,
is different for different genes, depending on the embryological
origin of the cells. (15)
The above discussion is centred around the Group 1 tumours
of Levine and Metz (40) i.e. the APUDOMAS, but there is a considerable
number of ectopic hormonal syndromes which are associated with
non-APUD derived tumours (Group 2). This group is composed of a
heterogeneous collection of tumours (see Table 4) of endocrine
and non-endocrine cells. They are, however, all derived from either
mesoderm or endoderm (40) and it is possible that the shared
embryological origin is sufficient to create a pattern in the
same way as with the APUD cells. It may be significant that Group 2
tumours are less well differentiated morphologically than Group f 1 •
tumours and are much more frequently associated with the production
of fetal substances (4). This may reflect a greater degree of dedifferentiatior
which would account for the heterogeneity of this group.
SUMMARY AMD CONCLUSIONS
The phenomenon of ectopic hormone production by tumours
has been discussed and the need for accurate documentation emphasized.
Theories on the mechanism of ectopic hormone production require
good supporting evidence for the exact cells of origin of the hormone,
and such evidence has led to the emergence of the APUD theory for
certain ectopic humoral syndromes. This theory, which also has
wide implications for polypeptide endocrinology, offers a good
explanation for the Group 1 tumours, especially in the light
of the evidence for neoplasia producing derepression of the genome
and a return to an earlier competence. It was suggested that the
behaviour of APUD cells in neoplasia is evidence for differential
repression of the genome. More knowledge of the mechanisms of
cell differentiation should' provide an explanation for how this occurs.,
as well as increasing -understanding of Group 2 tumours.
Ectopic hormone production in tumours, which,at present,
is regarded as a relatively rare occurrence, may have wider implications
in neoplasia. The behaviour of malignant cells may stem from the
production by them of substances normally produced only in the
course of development. Our previous knowledge of hormone excess
syndromes has allowed us to document the ectopic hormone phenomenon
but this may just be one example of a widespread effect.
TABLE 1
a) Cytochemical characteristics of APUD cells
1. Fluorogenic amine content ( catecholamine, 5-HT etc.)
2. Amine precursor uptake.
5. Amino-acid decarboxylase.
4. High side-chain carboxyl (masked metachromasia)
5. High non-specific esterase or cholinesterase.
6. High ^-glycerophosphatedehydrogenase.
7. Specific immunofluorescence ( if known hormone present)
b) Ultrastructural chara cteristics
1. Low rough endoplasmic reticulum (e.r.)
2. High smooth e.r.
3. Electron-dense mitochondria.
4. Prominent microtubules.
5. Large amounts of free ribosomes.
6. Presense of membrane-bound secretion vesicles.
TABLE 2




PANCREATIC ISLET B-CELL (INSULIN)
PANCREATIC ISLET A2-CELL (GLUGAGON)
PANCREATIC ISLET A-]-CELL (GASTRIN?)
THYROID C-CELL (CALCITONIN)
STOMACH^ARGYROPHIL CELL (GASTRIN)
" STOMACH-ENTEROCHROMAEFIN CELL (SECRETIN)
INTESTINE-ARGYROPHIL CELL (CHOLECYSTOKININ-PANCREOZYMIN).
INTESTINE-ENTEROCHROI4AEPIN CELL (SECRETIN,GLUCAGON)
CAROTID BODY TYPE I CELL(?)
LUNG ENDOCRINE CELL (EEYRTER) (?)
See ref 15 and6l.


































































































c P vasopressin (P)















































* The best available documentation of hormone secretion is presented according to the following code: Hormone localized in tumor(T), or found in
plasma or serum(S), or urine(U). There has been demonstrated: (1) a significant arteriovenous gradient across the tumor bed, (2) secretion of the
hormono by tumor cells in tissue or cell culture, or (3) localization of hormone in the tumor by specific histofluorescent technique. The hormone has
been identified by (4) radioimmunoassay or by (5) bioassay or physicochemical method,
t +, Dcfinito documentation,
t P, probable or possible documentation.
§ Possibly transitional.
( Transitional group.
Documentation of Hormone Secretion dy Group I Tumors
Catechol¬





















































































P p P (T)
+
(4,5)
P P see Table 6
• Tho best available documentation of hormone secretion is presented according to the following code: Hormone localized in tumor(T), or found in
plasma or scrum(S), or urinc(U). There has been demonstrated: (1) a significant arteriovenous gradient across the tumor bed, (2) sccrcu'on of the
hormono by tumor cells in tissue or cell culture, or (3) localization of hormone in the tumor by specific histofiuorcsccnt technique. The hormone has
been identified by (4) radioimmunoassay or by (5) bioassay or physicochemical method.
t •(-, Definite documentation.
} 1>, probable or possible documentation.
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